Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Association between endostatin and mortality in patients with acute dyspnoea, with or without congestive heart failure: a single-centre, prospective, observational study

Yaghoubi, Alexander LU ; Heijl, Caroline LU orcid ; Khoshnood, Ardavan M LU orcid ; Wändell, Per Erik ; Carlsson, Axel C and Wessman, Torgny LU (2025) In BMJ Open 15.
Abstract
Objective The aim of this study was to assess associations between endostatin levels and short-term mortality in unsorted acute hospitalised dyspnoea patients with or without congestive heart failure (CHF), adjusted for common cardiovascular risk factors.Design, setting and participants In this prospective observational study, 723 hospitalised patients who visited the emergency department at Skåne University Hospital, Sweden, between 2013 and 2018 were included. Of these, 276 had a history of CHF. The association between endostatin levels and 1 month and 3-month mortality was evaluated, stratified by whether patients had a history of CHF or not.Results Patients with prior CHF had higher endostatin levels, higher short-term mortality and... (More)
Objective The aim of this study was to assess associations between endostatin levels and short-term mortality in unsorted acute hospitalised dyspnoea patients with or without congestive heart failure (CHF), adjusted for common cardiovascular risk factors.Design, setting and participants In this prospective observational study, 723 hospitalised patients who visited the emergency department at Skåne University Hospital, Sweden, between 2013 and 2018 were included. Of these, 276 had a history of CHF. The association between endostatin levels and 1 month and 3-month mortality was evaluated, stratified by whether patients had a history of CHF or not.Results Patients with prior CHF had higher endostatin levels, higher short-term mortality and were more likely to have CHF as discharge diagnosis. In a fully adjusted model, endostatin was independently associated with 3-month mortality (HR=1.01 per 1 ng/mL increment of endostatin; 95% CI 1.00 to 1.02; p=0.016). No evidence of association was identified with 1-month mortality.Conclusions Endostatins are potential biomarkers for 3 months’ mortality in patients hospitalised with CHF seeking emergency care with acute dyspnoea. Further studies are needed in different settings to assess the predictive value of endostatins in patients with CHF.Data are available on reasonable request. Technical appendix, statistical code and datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dyspnea, Endostatin, Mortality, Heart Failure
in
BMJ Open
volume
15
article number
e085238
publisher
BMJ Publishing Group
external identifiers
  • pmid:39800400
  • scopus:85215354045
ISSN
2044-6055
DOI
10.1136/bmjopen-2024-085238
language
English
LU publication?
yes
id
1d967c1d-568e-45b2-aa1a-1735512492d2
date added to LUP
2025-01-13 11:30:32
date last changed
2025-04-04 15:30:54
@article{1d967c1d-568e-45b2-aa1a-1735512492d2,
  abstract     = {{Objective The aim of this study was to assess associations between endostatin levels and short-term mortality in unsorted acute hospitalised dyspnoea patients with or without congestive heart failure (CHF), adjusted for common cardiovascular risk factors.Design, setting and participants In this prospective observational study, 723 hospitalised patients who visited the emergency department at Skåne University Hospital, Sweden, between 2013 and 2018 were included. Of these, 276 had a history of CHF. The association between endostatin levels and 1 month and 3-month mortality was evaluated, stratified by whether patients had a history of CHF or not.Results Patients with prior CHF had higher endostatin levels, higher short-term mortality and were more likely to have CHF as discharge diagnosis. In a fully adjusted model, endostatin was independently associated with 3-month mortality (HR=1.01 per 1 ng/mL increment of endostatin; 95% CI 1.00 to 1.02; p=0.016). No evidence of association was identified with 1-month mortality.Conclusions Endostatins are potential biomarkers for 3 months’ mortality in patients hospitalised with CHF seeking emergency care with acute dyspnoea. Further studies are needed in different settings to assess the predictive value of endostatins in patients with CHF.Data are available on reasonable request. Technical appendix, statistical code and datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.}},
  author       = {{Yaghoubi, Alexander and Heijl, Caroline and Khoshnood, Ardavan M and Wändell, Per Erik and Carlsson, Axel C and Wessman, Torgny}},
  issn         = {{2044-6055}},
  keywords     = {{Dyspnea; Endostatin; Mortality; Heart Failure}},
  language     = {{eng}},
  month        = {{01}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{BMJ Open}},
  title        = {{Association between endostatin and mortality in patients with acute dyspnoea, with or without congestive heart failure: a single-centre, prospective, observational study}},
  url          = {{http://dx.doi.org/10.1136/bmjopen-2024-085238}},
  doi          = {{10.1136/bmjopen-2024-085238}},
  volume       = {{15}},
  year         = {{2025}},
}